UNSPSC 51172110: Prozapine

This classification denotes an antispasmotic agent with the molecular formula C20H25NO2, chemically known as 1-(3,3-diphenylpropyl)azepane hydrochloride but generally known as prozapine hydrochloride, which bears US NIH Compound Identifier 71127. European Medicines Agency schedules Prozapine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10154MIG. Most nations schedule prozapine under HS 29339930 and SITC 51577. As of Q4 2014, PROZAPINE remains the US FDA Preferred Term for this commodity.

Prozapine bears US NLM identifiers UMLS ID C0072512 and NCI Concept Code C73167. SMILES: C1CCCN(CC1)CCC(C2=CC=CC=C2)C3=CC=CC=C3.

UNSPSC 51172110 Prozapine, a Commodity code, covers pharmaceutical products used in clinical and correctional-facility testing and treatment contexts. State and local governments buy prozapine and related drugs primarily for offender drug-screening programs, therapeutic pharmacy initiatives, and broader pharmaceutical supply contracts serving public health systems, correctional agencies, and employee health plans. Issuing bodies include county corrections and community supervision departments, state health and human services commissions, and multistate cooperative purchasing alliances administering contracts on behalf of participating state and local jurisdictions. The scope of work involves both direct pharmaceutical supply contracts with manufacturers and service contracts that bundle specimen collection, lab testing, and related clinical services where prozapine and similar compounds may be employed as screening or confirmatory agents.

Recent activity shows Collin County Community Supervision and Corrections Department (Texas) issuing RFP 2026-327 for offender specimen collection and drug testing services with proposals due July 23, 2026—a two-year contract estimated at $600,000 covering approximately 25,031 annual tests across two sites in Plano and McKinney, requiring SAMHSA or CAP lab certification. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather market intelligence on direct-to-manufacturer pharmaceutical programs that may incorporate pozapine products, signaling state-level interest in alternative distribution models. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products with a March 26, 2026 response deadline, establishing two-year contracts effective July 1, 2026 for distribution through three authorized wholesalers across Minnesota, Oregon, and participating jurisdictions. Geographic activity concentrates in Texas and the upper Midwest, with Texas showing the most recent and concrete procurement volume tied directly to correctional and clinical testing demand.